1. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry 
Anthony Mato, Chadi Nabhan, Neil E. Kay, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Shriya Bhushan, Kristen Sullivan, E. Dawn Flick, Jeff P. Sharman 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 2, Pages e2 (February 2018)
DOI: /j.clml
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Line of Therapy and Genetic Risk Group Stratification in the Connect CLL Registry
Abbreviations: CLL = chronic lymphocytic leukemia; LOT1 = first line of therapy; LOT≥2 = second or further line of therapy.
Clinical Lymphoma, Myeloma and Leukemia  , e2DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Kaplan-Meier Curves of Event-Free Survival for All Patients Enrolled at (A) First Line of Therapy (LOT1) and (B) Second or Further Line of Therapy (LOT≥2), Stratified by Risk. Data Cutoff Was August 25, 2015
Abbreviation: CI = confidence interval; NR = not reached. (The 15 most frequent regimens are provided in Supplemental Table 3; available in the online version).
Clinical Lymphoma, Myeloma and Leukemia  , e2DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 3
Kaplan-Meier Curves for Event-Free Survival in Unfavorable-Risk and Favorable-Risk Patients at First Line of Therapy (LOT1). (A) Event-Free Survival for Patients Receiving FCR (Fludarabine, Cyclophosphamide, Rituximab). (B) Event-Free Survival for Patients Receiving BR (bendamustine, rituximab)
Abbreviation: CI = confidence interval.
Clinical Lymphoma, Myeloma and Leukemia  , e2DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions